{"id":745088,"date":"2015-10-28T08:00:00","date_gmt":"2015-10-28T08:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-from-merck-awarded-prix-galien-usa-2015-best-biotechnology-product-award\/"},"modified":"2025-11-07T01:24:51","modified_gmt":"2025-11-07T06:24:51","slug":"keytruda-pembrolizumab-from-merck-awarded-prix-galien-usa-2015-best-biotechnology-product-award","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-from-merck-awarded-prix-galien-usa-2015-best-biotechnology-product-award\/","title":{"rendered":"KEYTRUDA\u00ae (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1<br \/>\n      therapy for the treatment of advanced melanoma and metastatic non-small<br \/>\n      cell lung cancer in patients whose disease has progressed after other<br \/>\n      therapies, received the Prix Galien USA 2015 Award for Best<br \/>\n      Biotechnology Product.\n    <\/p>\n<p>\n      \u201cAs a company built on a foundation of scientific excellence, Merck is<br \/>\n      honored to again have been chosen as a recipient of this prestigious<br \/>\n      award,\u201d said Dr. Roger M. Perlmutter, president, Merck Research<br \/>\n      Laboratories. \u201cThis achievement is a testament to the remarkable<br \/>\n      contributions of everyone at Merck, as well as the many physicians and<br \/>\n      patients who participated in our clinical trials, in helping to bring<br \/>\n      KEYTRUDA to patients.\u201d\n    <\/p>\n<p>\n      The Prix Galien Award recognizes the pharmaceutical industry\u2019s<br \/>\n      outstanding achievement in the development of new medicines. An<br \/>\n      internationally recognized award, the Prix Galien was founded in France<br \/>\n      in 1969 by French pharmacist Roland Mehl and is considered the highest<br \/>\n      accolade for pharmaceutical research and development.\n    <\/p>\n<p>\n      This latest award for KEYTRUDA is Merck\u2019s seventh Prix Galien USA award<br \/>\n      in nine years. The company was previously recognized for ZOSTAVAX<br \/>\n      (2013), VICTRELIS (2012), ROTATEQ (2010), ISENTRESS (2008) and JANUVIA<br \/>\n      and GARDASIL (2007). In total, around the world, Merck has won the Prix<br \/>\n      Galien 40 times, making Merck the most-awarded company of all time.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global health care leader working to help the world<br \/>\n      be well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to health care through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51211283&amp;newsitemid=20151028005722&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=551d9149fc8f86d8ad222a722cb95be6\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51211283&amp;newsitemid=20151028005722&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=bdfdb0e8e77d52600811061aec8ced33\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51211283&amp;newsitemid=20151028005722&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=aea19d2dc2e1331c325d549106f82d6e\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51211283&amp;newsitemid=20151028005722&amp;lan=en-US&amp;anchor=YouTube&amp;index=4&amp;md5=9cbbf27c64695759d1abd0d4c86cab5a\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co. Inc., Kenilworth, NJ, USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, NJ, USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the United States Private Securities<br \/>\n      Litigation Reform Act of 1995. These statements are based upon the<br \/>\n      current beliefs and expectations of the company\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. If underlying<br \/>\n      assumptions prove inaccurate or risks or uncertainties materialize,<br \/>\n      actual results may differ materially from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51211283&amp;newsitemid=20151028005722&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=5&amp;md5=8b4c2fcf803c40110aa252afba8800d1\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20151028005722r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><span class=\"bwct31415\" \/><\/span><\/p>\n<p>       Media:<br \/>Pamela Eisele, 267-305-3558     <\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy for the treatment of advanced melanoma and metastatic non-small cell lung cancer in patients whose disease has progressed after other therapies, received the Prix Galien USA 2015 Award for Best Biotechnology Product. \u201cAs a company built on a foundation of scientific excellence, Merck is honored to again have been chosen as a recipient of this prestigious award,\u201d said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cThis achievement is a testament to the remarkable contributions of everyone at Merck, as well as the many physicians and patients who participated in our clinical trials, in helping to bring KEYTRUDA to patients.\u201d The Prix Galien Award recognizes the pharmaceutical industry\u2019s outstanding achievement in the development of new medicines. An internationally recognized award, the Prix Galien was founded in France<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745088","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>KEYTRUDA\u00ae (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-from-merck-awarded-prix-galien-usa-2015-best-biotechnology-product-award\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KEYTRUDA\u00ae (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy for the treatment of advanced melanoma and metastatic non-small cell lung cancer in patients whose disease has progressed after other therapies, received the Prix Galien USA 2015 Award for Best Biotechnology Product. \u201cAs a company built on a foundation of scientific excellence, Merck is honored to again have been chosen as a recipient of this prestigious award,\u201d said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cThis achievement is a testament to the remarkable contributions of everyone at Merck, as well as the many physicians and patients who participated in our clinical trials, in helping to bring KEYTRUDA to patients.\u201d The Prix Galien Award recognizes the pharmaceutical industry\u2019s outstanding achievement in the development of new medicines. An internationally recognized award, the Prix Galien was founded in France\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-from-merck-awarded-prix-galien-usa-2015-best-biotechnology-product-award\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:24:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-from-merck-awarded-prix-galien-usa-2015-best-biotechnology-product-award\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-from-merck-awarded-prix-galien-usa-2015-best-biotechnology-product-award\\\/\",\"name\":\"KEYTRUDA\u00ae (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-10-28T08:00:00+00:00\",\"dateModified\":\"2025-11-07T06:24:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-from-merck-awarded-prix-galien-usa-2015-best-biotechnology-product-award\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-from-merck-awarded-prix-galien-usa-2015-best-biotechnology-product-award\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-from-merck-awarded-prix-galien-usa-2015-best-biotechnology-product-award\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"KEYTRUDA\u00ae (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KEYTRUDA\u00ae (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-from-merck-awarded-prix-galien-usa-2015-best-biotechnology-product-award\/","og_locale":"en_US","og_type":"article","og_title":"KEYTRUDA\u00ae (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy for the treatment of advanced melanoma and metastatic non-small cell lung cancer in patients whose disease has progressed after other therapies, received the Prix Galien USA 2015 Award for Best Biotechnology Product. \u201cAs a company built on a foundation of scientific excellence, Merck is honored to again have been chosen as a recipient of this prestigious award,\u201d said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cThis achievement is a testament to the remarkable contributions of everyone at Merck, as well as the many physicians and patients who participated in our clinical trials, in helping to bring KEYTRUDA to patients.\u201d The Prix Galien Award recognizes the pharmaceutical industry\u2019s outstanding achievement in the development of new medicines. An internationally recognized award, the Prix Galien was founded in France","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-from-merck-awarded-prix-galien-usa-2015-best-biotechnology-product-award\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:24:51+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-from-merck-awarded-prix-galien-usa-2015-best-biotechnology-product-award\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-from-merck-awarded-prix-galien-usa-2015-best-biotechnology-product-award\/","name":"KEYTRUDA\u00ae (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-10-28T08:00:00+00:00","dateModified":"2025-11-07T06:24:51+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-from-merck-awarded-prix-galien-usa-2015-best-biotechnology-product-award\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-from-merck-awarded-prix-galien-usa-2015-best-biotechnology-product-award\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-from-merck-awarded-prix-galien-usa-2015-best-biotechnology-product-award\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"KEYTRUDA\u00ae (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"8ade8859-4fa4-4e47-bbdc-93d6cb1fd3d9","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745088","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745088\/revisions"}],"predecessor-version":[{"id":3674581,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745088\/revisions\/3674581"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745088"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745088"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}